Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety

Bibliography

• Roger VL, Go AS, Lloyd-Jones DM, Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 2012;125(1):e2-e220
   PubMed Web of Science ®Google Scholar
• Genovesi S, Pogliani D, Faini A, Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005;46(5):897-902
   PubMed Web of Science ®Google Scholar
• Wizemann V, Tong L, Satayathum S, Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77(12):1098-106
   PubMed Web of Science ®Google Scholar
• Atar I, Konaş D, Açikel S, Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol 2006;106(1):47-51
   PubMed Web of Science ®Google Scholar
• Vázquez E, Sanchez-Perales C, Garcia-Garcia F, Atrial fibrillation in incident dialysis patients. Kidney Int 2009;76(3):324-30
   PubMed Web of Science ®Google Scholar
• Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28(10):973-7
   PubMed Web of Science ®Google Scholar
• Seliger SL, Gillen DL, Longstreth WT Jr, Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003;64(2):603-9
   PubMed Web of Science ®Google Scholar
• Vázquez E, Sánchez-Perales C, Borrego F, Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000;140(6):886-90
   PubMed Web of Science ®Google Scholar
• Genovesi S, Vincenti A, Rossi E, Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008;51(2):255-62
   PubMed Web of Science ®Google Scholar
• Hart GR, Pearce AL, Aguilar IM. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
   PubMed Web of Science ®Google Scholar
• Lip GY, Blann AD. Endothelium and fibrinolysis in hypertension: important facets of a prothrombotic state? Hypertension 2008;52(2):218-19
   PubMed Web of Science ®Google Scholar
• Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009;373(9658):155-66
   PubMed Web of Science ®Google Scholar
• Landray MJ, Wheeler DC, Lip GY, Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004;43(2):244-53
   PubMed Web of Science ®Google Scholar
• Adams MJ, Irish AB, Watts GF, Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb Res 2008;123(2):374-80
   PubMed Web of Science ®Google Scholar
• Tanaka H, Sonoda M, Kashima K, Impact of decreased renal function on coagulation and fibrinolysis in patients with non-valvular atrial fibrillation. Circ J 2009;73(5):846-50
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108(17):2154-69
   PubMed Web of Science ®Google Scholar
• Tsukamoto Y, Takahashi W, Takizawa S, Chronic kidney disease in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2011; [Epub ahead of print]
   Google Scholar
• Hoshino H, Itoh Y, Yamada S, Clinical features and neurologic severity in stroke patients with mild to moderate renal dysfunction. J Stroke Cerebrovasc Dis 2012;21(5):343-9
   PubMed Web of Science ®Google Scholar
• Ani C, Ovbiagele B. Relation of baseline presence and severity of renal disease to long-term mortality in persons with known stroke. J Neurol Sci 2010;288(1-2):123-8
   PubMed Web of Science ®Google Scholar
• Bos MJ, Koudstaal PJ, Hofman A, Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke 2007;38(12):3127-32
   PubMed Web of Science ®Google Scholar
• Wiesholzer M, Harm F, Tomasec G, Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 2001;21:35-9
   PubMed Web of Science ®Google Scholar
• Vázquez E, Sánchez-Perales C, Lozano C, Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 2003;92:868-71
   PubMed Web of Science ®Google Scholar
• Chou CY, Kuo HL, Wang SM, Outcome of atrial fibrillation among patients with end-stage renal disease. Nephrol Dial Transplant 2010;25(4):1225-30
   PubMedGoogle Scholar
• Gage BF, Waterman AD, Shannon W, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864-70
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-72
   PubMed Web of Science ®Google Scholar
• Kuang D, You H, Ding F, Intima-media thickness of the carotid artery and its correlation factors in maintenance hemodialysis patients: a cross-sectional study. Blood Purif 2009;28(3):181-6
   PubMed Web of Science ®Google Scholar
• Balsam A, El Kossi MM, Lord R, Cardiovascular disease on hemodialysis: predictors of atherosclerosis and survival. Hemodial Int 2009;13(3):278-85
   PubMed Web of Science ®Google Scholar
• Lai HM, Aronow WS, Kalen P, Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis 2009;2:33-7
   Google Scholar
• Olesen JB, Lip GY, Kamper AL, Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367(7):625-35
   PubMed Web of Science ®Google Scholar
• Abbott KC, Trespalacios FC, Taylor AJ, Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol 2003;4:1
   PubMedGoogle Scholar
• Knoll F, Sturm G, Lamina C, Coumarins and survival in incident dialysis patients. Nephrol Dial Transplant 2012;27(1):332-7
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 2007;50(3):433-40
   PubMed Web of Science ®Google Scholar
• Reinecke H, Brand E, Mesters R, Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009;20(4):705-11
   PubMed Web of Science ®Google Scholar
• Chan KE, Lazarus JM, Thadhani R, Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20(10):2223-33
   PubMed Web of Science ®Google Scholar
• Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol 2008;3(5):1504-10
   PubMed Web of Science ®Google Scholar
• Chatrou ML, Winckers K, Hackeng TM, Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev 2012;26(4):155-66
   PubMed Web of Science ®Google Scholar
• Chan KE, Lazarus JM, Thadhani R, Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009;20(4):872-81
   PubMed Web of Science ®Google Scholar
• Toyoda K, Fujii K, Fujimi S, Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am J Kidney Dis 2005;45(6):1058-66
   PubMed Web of Science ®Google Scholar
• Limdi NA, Limdi MA, Cavallari L, Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010;56(5):823-31
   PubMed Web of Science ®Google Scholar
• Brodsky SV, Satoskar A, Chen J, Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis 2009;54(6):1121-6
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100
   PubMed Web of Science ®Google Scholar
• Gage BF, Yan Y, Milligan PE, Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151(3):713-19
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stähle H, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64(3):292-303
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010;121(13):1523-32
   PubMed Web of Science ®Google Scholar
• Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010;115(1):15-20
   PubMed Web of Science ®Google Scholar
• Bereznicki LR, Peterson GM. New antithrombotics for atrial fibrillation. Cardiovasc Ther 2010;28(5):278-86
   PubMed Web of Science ®Google Scholar
• Ordovás Baines JP, Climent Grana E, Jover Botella A, Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban. Farm Hosp 2009;33(3):125-33
   PubMedGoogle Scholar
• Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011;31(3):326-43
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stähle H, Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49(4):259-68
   PubMed Web of Science ®Google Scholar
• Ryn V.J, Stangier J, Haertter S, Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27
   PubMed Web of Science ®Google Scholar
• Eerenberg SE, Kamphuisen WP, Sijpkens KM, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Briefing information for the September 20, 2010 meeting of the cardiovascular and renal drugs advisory committee. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226704.pdf [Accessed on 9 July 2012]
   Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123(21):2363-72
   PubMed Web of Science ®Google Scholar
• Ezekowitz DM, Reilly AP, Nehmiz G, Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-26
   PubMed Web of Science ®Google Scholar
• Koudstaal PJ, Ciabattoni G, van Gijn J, Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke 1993;24(2):219-23
   PubMed Web of Science ®Google Scholar
• McConnell JP, Cheryk LA, Durocher A, Urinary 11-dehydro-thromboxane B(2) and coagulation activation markers measured within 24 h of human acute ischemic stroke. Neurosci Lett 2001;313(1-2):88-92
   PubMed Web of Science ®Google Scholar
• Foegh ML, Zhao Y, Madren L, Urinary thromboxane A2 metabolites in patients presenting in the emergency room with acute chest pain. J Intern Med 1994;235(2):153-61
   PubMed Web of Science ®Google Scholar
• Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397-402
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92
   PubMed Web of Science ®Google Scholar
• Connolly JS, Eikelboom J, Joyner C, Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Antman EM, Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160(4):635-41
   PubMed Web of Science ®Google Scholar
• Quinn RR, Naimark DM, Oliver MJ, Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. Am J Kidney Dis 2007;50(3):421-32
   PubMed Web of Science ®Google Scholar